SCHEMBL13036090

SCHEMBL13036090

Cc1ccc(F)c(-c2c(C)noc2C)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.47
POLB P06746 1/20 0.47
CASP3 P42574 1/20 0.47
RAB9A P51151 1/20 0.47
SENP7 Q9BQF6 1/20 0.47
FFAR1 O14842 1/20 0.45
BRD4 O60885 10/20 0.44
BRD2 P25440 2/20 0.44
ERN1 O75460 1/20 0.44
NISCH Q9Y2I1 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
AR P10275 1/20 0.40
P2RX7 Q99572 1/20 0.39
CYP1A2 P05177 2/20 0.39
CYP3A4 P08684 2/20 0.39
CYP2C19 P33261 1/20 0.39
ALOX15 P16050 1/20 0.39
HSD17B10 Q99714 1/20 0.39
MLYCD O95822 1/20 0.39
BRD3 Q15059 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18249941 0.83 FFAR1 (0.43) NPC1POLBCASP3RAB9ASENP7
SCHEMBL12362774 0.83 ERN1 (0.49) FFAR1BRD4BRD2ERN1AR
SCHEMBL16404611 0.79 BRD4 (0.56) NPC1POLBCASP3RAB9ASENP7
SCHEMBL18258249 0.77 ALDH1A1 (0.44) NPC1POLBRAB9AFFAR1BRD4
SCHEMBL15314278 0.77 BRD4 (0.50) FFAR1BRD4BRD2ERN1BRD3
SCHEMBL18359486 0.73 BRD4 (0.50) BRD4BRD2ERN1CYP1A2CYP3A4
SCHEMBL30522525 0.73 MAP4K4 (0.43) NPC1POLBCASP3RAB9ASENP7
SCHEMBL14987845 0.72 BRD4 (0.48) NPC1POLBCASP3RAB9ASENP7
SCHEMBL13036077 0.72 BRD4 (0.56) BRD4BRD2ERN1MLYCDBRD3
SCHEMBL13830012 0.72 NISCH (0.52) POLBCASP3SENP7NISCHL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8841331-B2 Inhibitors of human immunodeficiency virus replication GILEAD SCIENCES, INC. (US) 2014-09-23 US disclosed
US-8841331-B2 Inhibitors of human immunodeficiency virus replication GILEAD SCIENCES, INC. (US) 2014-09-23 US disclosed
US-20130203747-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION GILEAD SCIENCES, INC. (US) 2013-08-08 US disclosed
US-8338441-B2 Inhibitors of human immunodeficiency virus replication GILEAD SCIENCES, INC. (US) 2012-12-25 US disclosed
US-8338441-B2 Inhibitors of human immunodeficiency virus replication GILEAD SCIENCES, INC. (US) 2012-12-25 US disclosed
WO-2010130034-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-18 WO disclosed
US-20100292227-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) 2010-11-18 US disclosed
US-20100292227-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292227-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION RTF2, REV1, RTF1 NPC1 1129/4885POLB 76/4885CASP3 3217/4885
US-20130203747-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION RTF2, REV1, RTF1 NPC1 1129/4885POLB 76/4885CASP3 3217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.